Ellume is an Australian-based digital diagnostics company that develops, manufactures and commercializes high-performance, connected products for health professionals and consumers.
The company focuses on the detection of common illnesses which affect the global population and our products differ from conventional diagnostics through performance, digital connectivity, actionability
Ellume has developed novel detection technology powered by a unique quantum dot nanoparticle, which integrates optics, electronics, biologics
It has a global partnership in consumer health with GlaxoSmithKline, a global partnership with QIAGEN in latent tuberculosis, and a range of professional products under the ellume·lab brand which are scheduled for US launch in 2020.
How is the company combating the flu?
At the end of 2018, Ellume formed
The company is focused on developing innovative products which enable effective and efficient healthcare for common, burdensome illness where early accurate diagnosis could significantly improve patient outcomes.
Ellume products are distinguished by their technical performance, ease of use, rapid time to result and connectivity.
Commenting on the strategic partnership,
Who has the company brought on board to further growth?
Last month, Ellume announced the appointment of David Green as Chief Financial Officer and Company
David Green has over 25 years’ experience in senior finance roles covering private treaty and public company transactions, with a strong background in pre-IPO and start-up businesses.
David commenced his career with EY in both England and
Mark Boyle brings over 20 years’ of executive management experience in in-vitro diagnostic and biotechnology markets to his new role in the US. Previously, he was the President of Cellestis Inc. and continued on through the acquisition by Qiagen to successfully lead the company’s global business portfolio in tuberculosis management.
During his tenure from 2001 to 2016, sales of QuantiFERON diagnostics grew
“Mark and David both bring formidable experience and leadership to our expanding team,” said
“Mark’s experience in successfully scaling the sales of QuantiFERON in the US gives us confidence and a successful framework as we prepare to replicate this with our ellume·lab product, and David’s experience with public markets at Sigma, Alchemia and others is proving fundamental as we position the company to potentially transition onto the ASX later this year.”